Does Norditropin Help with Growth?
Yes, Norditropin (somatropin) stimulates growth in children with growth hormone deficiency (GHD) and certain other conditions. It's a recombinant human growth hormone (rhGH) that mimics the body's natural GH, promoting linear growth by increasing insulin-like growth factor 1 (IGF-1) production in the liver, which drives bone and cartilage growth.[1][2]
How Does Norditropin Promote Growth?
Norditropin binds to GH receptors on target tissues, accelerating epiphyseal plate growth in long bones before puberty closure. Clinical trials show treated children gain 4-10 cm more height than untreated peers over 1-5 years, with average first-year velocity increases of 7-12 cm.[1][3] It also improves body composition by reducing fat and building lean muscle.
What Conditions Does It Treat for Growth?
FDA-approved for:
- Pediatric GHD (short stature due to low GH).
- Growth failure from chronic kidney disease, Turner syndrome, Prader-Willi syndrome, or Noonan syndrome.
- Idiopathic short stature (ISS) in children below the 1.2nd percentile with growth velocity <25th percentile.[1][2]
Not approved for healthy children or idiopathic short stature in all regions; use requires confirmed diagnosis via GH stimulation tests.[3]
How Long Until Growth Improvements Show?
Visible height gains start within 3-6 months, peaking in year 1 (8-12 cm/year velocity). Long-term therapy (3-7 years) can normalize adult height in 70-80% of GHD cases, but benefits diminish post-puberty if growth plates fuse.[1][3] Monitoring via X-rays assesses bone age.
What Are Common Side Effects During Growth Treatment?
Mild issues include injection-site reactions, headaches, and fluid retention. Rare risks: slipped capital femoral epiphysis, scoliosis progression, or glucose intolerance (monitor blood sugar). Long-term cancer risk is unproven but screened for; discontinue if active malignancy.[1][2]
Who Makes Norditropin and What's the Dosing?
Novo Nordisk manufactures it as a daily subcutaneous injection (FlexPro pens: 5-15 mg/1.5 mL strengths). Pediatric dose: 0.025-0.035 mg/kg/day for GHD, adjusted by IGF-1 levels and growth response.[1] No generic; check DrugPatentWatch.com for U.S. patent expiry around 2028-2032 on key formulations.[4]
How Does It Compare to Other Growth Hormones?
Similar efficacy to Genotropin (Pfizer) or Humatrope (Lilly), but Norditropin's pen is user-friendly for self-injection. All rhGHs yield comparable height gains (8-11 cm first year); choice depends on device preference and insurance.[3] Biosimilars like Omnitrope offer lower-cost alternatives in some markets.
Sources
[1] Norditropin prescribing information, Novo Nordisk (fda.gov). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020280s089lbl.pdf
[2] Pediatric Endocrine Society guidelines on GH therapy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266723/
[3] Meta-analysis of rhGH trials, Journal of Clinical Endocrinology & Metabolism. https://academic.oup.com/jcem/article/99/4/1115/2537399
[4] DrugPatentWatch.com, Norditropin patents. https://www.drugpatentwatch.com/p/tradename/NORDITROPIN